Back to Search
Start Over
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
- Source :
-
Journal of autoimmunity [J Autoimmun] 2014 Nov; Vol. 54, pp. 1-7. Date of Electronic Publication: 2014 Oct 11. - Publication Year :
- 2014
-
Abstract
- Ruth Arnon and Michael Sela profoundly influenced the development of a model system to test new therapies in multiple sclerosis (MS). Their application of the animal model, known as experimental autoimmune encephalomyelitis (EAE), for the discovery of Copaxone, opened a new path for testing of drug candidates in MS. By measuring clinical, pathologic, and immunologic outcomes, the biological implications of new drugs could be elucidated. Using EAE they established the efficacy of Copaxone as a therapy for preventing and reducing paralysis and inflammation in the central nervous system without massive immune suppression. This had a huge impact on the field of drug discovery for MS. Much like the use of parabiosis to discover soluble factors associated with obesity, or the replica plating system to probe antibiotic resistance in bacteria, the pioneering research on Copaxone using the EAE model, paved the way for the discovery of other therapeutics in MS, including Natalizumab and Fingolimod. Future applications of this approach may well elucidate novel therapies for the neurodegenerative phase of multiple sclerosis associated with disease progression.<br /> (Copyright © 2014. Published by Elsevier Ltd.)
- Subjects :
- Animals
Fingolimod Hydrochloride
Glatiramer Acetate
History, 20th Century
History, 21st Century
Humans
Natalizumab
Sphingosine history
Sphingosine therapeutic use
Antibodies, Monoclonal, Humanized history
Antibodies, Monoclonal, Humanized therapeutic use
Encephalomyelitis, Autoimmune, Experimental drug therapy
Encephalomyelitis, Autoimmune, Experimental history
Encephalomyelitis, Autoimmune, Experimental immunology
Encephalomyelitis, Autoimmune, Experimental pathology
Immunosuppressive Agents history
Immunosuppressive Agents therapeutic use
Multiple Sclerosis diet therapy
Multiple Sclerosis history
Multiple Sclerosis immunology
Multiple Sclerosis pathology
Peptides history
Peptides therapeutic use
Propylene Glycols history
Propylene Glycols therapeutic use
Sphingosine analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1095-9157
- Volume :
- 54
- Database :
- MEDLINE
- Journal :
- Journal of autoimmunity
- Publication Type :
- Academic Journal
- Accession number :
- 25308417
- Full Text :
- https://doi.org/10.1016/j.jaut.2014.08.001